Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Co. (MRK) Stock Price & Market Analysis
MRK · NYSE · Pharmaceuticals
$143.37
▼ -$1.09(-0.75%)4:02 PM ET - vs previous closeQuote as of Nov 17, 2026, 4:02 PM EST
Regular-session close · Nov 17, 2026, 4:02 PM EST.
Long-term rangesAvailable historyHide
Historical range: 2000-11-17–2026-11-17. Earlier trading may not be included.
Loading price chart…
Data dates
PriceDelayedLast traded
FundamentalsLast checked
AnalystLast checked
NewsLatest item
What matters next
Next important events
- Feb 2, 2027Next earnings (est.) · After market closeEstimated · After market close · Last verified 2026-11-17
Countdown
77 days out
Reported fundamentals
MRK financial overview
Annual revenue
USD 65.01B
Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.
Revenue change
+1.3%
Change versus the fiscal year ended Dec 31, 2024.
Net profit margin
28.1%
Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.
These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.
Company · ProfileAbout Merck & Co. (MRK)Sector, leadership, and how Merck & Co. earns its revenue.Healthcare
Merck & Co.
NYSE · MRK · US
Company overview as of Nov 17, 2026.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Headquarters
- Rahway, NJ, United States
- Country
- US
- Founded
- 1891
- Employees
- 73,000
- CEO
- Mr. Robert M. Davis J.D.
- Exchange
- NYSE
Business model & operating resultsExplore business exposure, reported operating measures and the figures behind growth and profitability claims.
Narrative versus numbers
Demand is expanding
Supporting observation: 4.7%
Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · Source timestamp: Sep 30, 2026
Growth produces accounting profit
Supporting observation: 3.6%
Net margin; the source did not supply a reporting period. Do not compare this reading with the quarterly or fiscal-year figures above. A positive margin does not establish cash generation. · Source timestamp: Nov 17, 2026, 3:13 PM EST
The business generates cash after investment
Supporting observation: USD 5.52B
Latest free cash flow from the statement feed. It is not a forecast and may cover a different period from the fiscal-year figures above. · Source timestamp: Sep 30, 2026
These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.
Operating measures
- Revenue
- $18.09Bquarter ended Sep 30, 2026
- EPS
- $2.04quarter ended Sep 30, 2026
- Capital expenditure
- $1.04Bquarter ended Sep 30, 2026
- Free cash flow
- $5.52Bquarter ended Sep 30, 2026
- Free cash flow margin
- 30.5%quarter ended Sep 30, 2026
- Operating cash / net income
- 1.29×quarter ended Sep 30, 2026
- Revenue growth year over year
- 4.7%quarter ended Sep 30, 2026
Competitors & comparisonsCompare industry peers, reporting periods and related funds. Business mix and valuation bases may differ.
Valuation & fund comparisonsExplore dated peer valuations, growth comparisons and related funds.
Governance & sustainability
After hours
Regular hours: 9:30 AM–4:00 PM America/New_York
Next open: 2026-11-18 · 9:30 AM America/New_York
Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.
Shortcuts
With research tools focused: / search · W watchlist · C compare · F financials · E earnings · N news · T technicals · Esc close